Recombinant Canine PD-L1/B7-H1 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10746-B7

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10746-B7-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

NP_001278901.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all PD-L1/B7-H1 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived canine PD-L1/B7-H1 protein
Canine PD-L1/B7-H1
(Phe19-Arg236)
Accession # NP_001278901.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Phe19

Predicted Molecular Mass

51 kDa

SDS-PAGE

60-80 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.

When Recombinant Canine PD-1 Fc Chimera (Catalog # 10553-PD) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Canine PD-L1/B7-H1 Fc Chimera (Catalog # 10746-B7) binds with an ED50 of 0.30-4.50 µg/mL.

Scientific Data Images for Recombinant Canine PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Canine PD-L1/B7-H1 Fc Chimera Protein Binding Activity.

When Recombinant Canine PD-1 Fc Chimera (10553-PD) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Canine PD-L1/B7-H1 Fc Chimera (Catalog # 10746-B7) binds with an ED50 of 0.30-4.50 µg/mL.

Recombinant Canine PD-L1/B7-H1 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Canine PD-L1/B7-H1 Fc Chimera (Catalog # 10746-B7) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-80 kDa and 120-160 kDa, respectively.

Formulation, Preparation and Storage

10746-B7
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PD-L1/B7-H1

Programmed Death Ligand 1 (PD-L1), also known as B7-H1 and CD274, is a transmembrane glycoprotein in the B7 family of immune regulatory molecules. The B7 family is comprised of at least 10, structurally related members, and plays a central role in the regulation of T cell response by eliciting both positive co-stimulatory and negative inhibitory signals (1). Manipulation of B7 mediated signaling has shown potential in the treatment of autoimmunity, inflammatory diseases and cancer (1, 2). Mature PD-L1 consists of 1 IgV-like and 1 IgC-like region in the extracellular domain (ECD), a transmembrane region and a short intracellular domain. The ECD of canine PD-L1 shares 80% and 70% amino acid sequence identity with human and mouse PD-L1, respectively. In humans, alternative splicing can generate additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). PD-L1 binds to T cell B7-1/CD80 and PD-1 (4). PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, endothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma (4). It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells (5). It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development (5, 6). PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells (5-7). In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (8).

References

  1. Greenwald, R.J. et al. (2005) Annual Review of Immunology 23:515.
  2. Collins, Mary et al. (2005) Genome biology 6:223.
  3. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
  4. Daassi, D. et al. (2020) Nat Rev Immunol. 20:209.
  5. Ray, A. et al. (2015) Leukemia. 29:1441.
  6. Zhao, Y. et al. (2018) Oncotarget. 9:14803.
  7. Herold, M. et al. (2015) J. Immunol. 195:3584.
  8. Jiang, Y. et al. (2020) Canc lett. 468:72.

Long Name

Programmed Death Ligand 1

Alternate Names

B7-H1, B7H1, CD274, PDCD1L1, PDCD1LG1, PDL1

Entrez Gene IDs

29126 (Human); 60533 (Mouse); 499342 (Rat); 574058 (Porcine); 484186 (Canine); 102145573 (Cynomolgus Monkey)

Gene Symbol

CD274

UniProt

NP_001278901.1

Additional PD-L1/B7-H1 Products

Product Documents for Recombinant Canine PD-L1/B7-H1 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Canine PD-L1/B7-H1 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.